Kiladjian, Jean-Jacques; Ferrer-Marín, Francisca; Al-Ali, Haifa-Kathrin; Álvarez-Larrán, Alberto; Beggiato, Eloise; Bieniaszewska, María; Breccia, Massimo; Buxhofer-Ausch, Veronika; Cerna, Olga; Crisan, Ana-Manuela; Danaila, Catalin-Doru; de-Stefano, Valerio; Doehner, Konstanze; Empson, Victoria; Gora-Tybor, Joanna; Griesshammer, Martín; Grosicki, Sebastián; Guglielmelli, Paola; García-Gutiérrez, Valentín; Heidel, Florian-H; Illes, Arpad; Tomuleasa, Ciprian; James, Chloe; Koschmieder, Steffen; Krauth, María-Theresa; Krejcy, Kurt; Lázaroiu, Mihaela-Cornelia; Mayer, Jiri; Nagy, Zsolt-Gyoergy; Nicolini, Franck-Emmanuel; Palandri, Francesca; Pappa, Vassiliki; Reiter, Andreas-Johannes; Sacha, Tomász; Schlager, Stefanie; Schmidt, Stefan; Terpos, Evangelos; Unger, Martín; Woelfler, Albert; Xicoy, Blanca; Klade, Christoph
(Springer, 2024-07)
Interferon-based therapies, such as ropeginterferon alfa-2b have emerged as promising disease-modifying agents for myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET). Current ET treatments aim ...